Imipenem — Active Pharmaceutical Ingredient

Imipenem is an active pharmaceutical ingredient found in 3 FDA-approved drug products. Forms: POWDER, INJECTABLE. Routes: INTRAVENOUS, INJECTION, INTRAMUSCULAR.

This content is for informational purposes only. Always consult a healthcare professional.

Imipenem (3 brand names, 2 dosage forms, 3 routes)

Available dosage forms: POWDER, INJECTABLE.

Routes of administration: INTRAVENOUS, INJECTION, INTRAMUSCULAR.

Brand Names

  • IMIPENEM AND CILASTATIN
  • PRIMAXIN
  • RECARBRIO

Contraindications

RECARBRIO is contraindicated in patients with a history of known severe hypersensitivity (severe systemic allergic reaction such as anaphylaxis) to any component of RECARBRIO.

Adverse Reactions

The following serious adverse reactions are described in greater detail in the Warnings and Precautions section. Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Seizures and Other Central Nervous System Adverse Reactions [see Warnings and Precautions (5.2)] Increased Seizure Potential Due to Interaction with Valproic Acid [see Warnings and Precautions (5.3)] Clostridioides difficile-Associated Diarrhea (CDAD) [see Warnings and Precautions (5.4)]

Mechanism of Action

RECARBRIO is an antibacterial drug [see Microbiology (12.4)].

Overdosage

In the event of overdose, discontinue RECARBRIO, treat symptomatically, and institute general supportive treatment. Imipenem, cilastatin, and relebactam can be removed by hemodialysis [see Clinical Pharmacology (12.3)]. No clinical information is available on the use of hemodialysis to treat overdosage.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.